New hope for tough cancers: first test of experimental drug ZM008 begins
NCT ID NCT06451497
Summary
This early-stage trial is testing a new experimental drug called ZM008 in adults with advanced solid tumors who have run out of standard treatment options. The study will first determine safe doses of ZM008 given alone, then test it in combination with an existing immunotherapy drug called toripalimab. Researchers will monitor safety and look for early signs that the treatment can slow or shrink tumors in cancers like lung, breast, pancreatic, and others.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
-
NEXT Oncology
RECRUITINGAustin, TX 78758, Texas, 78758, United States
Contact
Contact Phone: •••-•••-••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.